Micron Shares Slide After Quarterly Outlook Misses Estimates
Memory-chip maker swung to a profit and posted higher revenue in its fiscal first quarter, though shares fell after the company's outlook missed estimates.
Lennar Revenue, Profit Slip Amid Challenging Housing Market
Lennar logged lower revenue and profit in its fiscal fourth quarter as the housing market was hurt by higher mortgage rates, sending its shares lower in post-market trading.
DOJ Alleges CVS Knowingly Contributed to Opioid Crisis in Suit
CVS ignored substantial evidence from multiple sources including its own pharmacists and internal data that indicated its stores were dispensing unlawful prescriptions, the complaint alleges.
Supreme Court to Consider TikTok Ban
The court scheduled fast-track oral arguments for Jan. 10 on whether the law violates the First Amendment.
Netflix Fined $4.8 Million by Dutch Watchdog Over Data-Handling Disclosures
The privacy regulator said the streaming platform hadn't given users adequate information on how it processes their personal data.
General Mills Stock Falls as Earnings Outlook Is Lowered
The packaged-food company posts better-than-expected fiscal second-quarter adjusted earnings.
Boeing Resumes Production of Airplanes, Including 737
The jet maker's factories in the Pacific Northwest have come back online using a safety-management system to identify potential issues, a company executive said.
U.S. Weighs Ban on Chinese-Made Router in Millions of American Homes
TP-Link is the bestselling router on Amazon-and has been linked to Chinese cyberattacks.
National Grid to Invest Up to $44.5 Billion in U.K. Electricity Transmission
The plan, which will nearly double the amount of energy that can be transported around the U.K., comes as energy utilities across Europe bet on a boom in demand amid rising electrification, industrial decarbonization, and AI applications.
EU Drug Regulator to Review Ozempic's Possible Link to Eye Condition
The European Union's drug regulator said it would review two studies that linked Novo Nordisk's blockbuster diabetes drug Ozempic to a rare eye condition.
(END) Dow Jones Newswires
December 18, 2024 19:00 ET (00:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments